9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Chronic Fluid Overload and Mortality in ESRD

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sustained fluid overload (FO) is considered a major cause of hypertension, heart failure, and mortality in patients with ESRD on maintenance hemodialysis. However, there has not been a cohort study investigating the relationship between chronic exposure to FO and mortality in this population. We studied the relationship of baseline and cumulative FO exposure over 1 year with mortality in 39,566 patients with incident ESRD in a large dialysis network in 26 countries using whole-body bioimpedance spectroscopy to assess fluid status. Analyses were applied across three discrete systolic BP (syst-BP) categories (<130, 130–160, and >160 mmHg), with nonoverhydrated patients with syst-BP=130–160 mmHg as the reference category; >200,000 FO measurements were performed over follow-up. Baseline FO value predicted excess risk of mortality across syst-BP categories (<130 mmHg: hazard ratio [HR], 1.51; 95% confidence interval [95% CI], 1.38 to 1.65; 130–160 mmHg: HR, 1.25; 95% CI, 1.16 to 1.36; >160 mmHg: HR, 1.30; 95% CI, 1.19 to 1.42; all P<0.001). However, cumulative 1-year FO exposure predicted a higher death risk ( P<0.001) across all syst-BP categories (<130 mmHg: HR, 1.94; 95% CI, 1.68 to 2.23; 130–160 mmHg: HR, 1.51; 95% CI, 1.35 to 1.69; >160 mmHg: HR, 1.62; 95% CI, 1.39 to 1.90). In conclusion, chronic exposure to FO in ESRD is a strong risk factor for death across discrete BP categories. Whether treatment policies that account for fluid status monitoring are preferable to policies that account solely for predialysis BP measurements remains to be tested in a clinical trial.

          Related collections

          Author and article information

          Journal
          J Am Soc Nephrol
          J. Am. Soc. Nephrol
          jnephrol
          jnephrol
          ASN
          Journal of the American Society of Nephrology : JASN
          American Society of Nephrology
          1046-6673
          1533-3450
          August 2017
          04 May 2017
          : 28
          : 8
          : 2491-2497
          Affiliations
          [* ]Center of Clinical Physiology, Clinical Epidemiology of Renal Diseases and Hypertension, Reggio Calabria, Italy;
          []Global Research and Development and
          []Clinical and Therapeutical Governance–Care Value Management, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany;
          []NephroCare Tassin-Charcot, Sainte Foy Les Lyon, France; and
          [§ ]Fresenius Dialysis Center St. Margit Hospital, Budapest, Hungary
          Author notes

          C.Z. and U.M. contributed equally to this work.

          Correspondence: Prof. Carmine Zoccali, Centro Nazionale delle Ricerche–Nefrologia, Ospedali Riuniti, 89124 Reggio Calabria, Italy. Email: carmine.zoccali@ 123456tin.it
          Article
          PMC5533242 PMC5533242 5533242 2016121341
          10.1681/ASN.2016121341
          5533242
          28473637
          109f3daa-e166-4720-a130-eb4c8a13a060
          Copyright © 2017 by the American Society of Nephrology
          History
          : 21 December 2016
          : 13 February 2017
          Page count
          Figures: 4, Tables: 3, Equations: 0, References: 24, Pages: 7
          Categories
          Clinical Epidemiology
          Custom metadata
          August 2017

          blood pressure,Epidemiology and outcomes,VOLUME EXPANSION,ESRD,hemodialysis,mortality risk

          Comments

          Comment on this article